{"DataElement":{"publicId":"5473464","version":"1","preferredName":"Therapeutic Procedure Delay Type","preferredDefinition":"A description of the therapy that was delayed.","longName":"Tx_Pdr_Dly_Typ","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5471450","version":"1","preferredName":"Therapeutic Procedure Delay","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.","longName":"2512834v1.0:2718948v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2718948","version":"1","preferredName":"Delay","preferredDefinition":"Delay; time during which some action is awaited; inactivity resulting in something being put off until a later time.","longName":"C25476","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Delay","conceptCode":"C25476","definition":"Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"433B5669-BDBA-05BF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-08","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2008-01-08","modifiedBy":"ONEDATA","dateModified":"2008-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3CE2BC17-DC42-084F-E053-F662850A2A9E","latestVersionIndicator":"Yes","beginDate":"2016-09-19","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-01","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18","administrativeNotes":"2022.11.1 Reviewed and released since in use. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3379560","version":"1","preferredName":"Therapy Type","preferredDefinition":"Class of the therapy that is currently being administered.","longName":"Tx_Type","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2991873","version":"1","preferredName":"Other","longName":"2991873","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7DC8B94A-9F2D-1457-E040-BB89AD430D33","latestVersionIndicator":"Yes","beginDate":"2010-01-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2010-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3684-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Radiation therapy","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"3282850","version":"1","preferredName":"Radiation Therapy","longName":"3282850","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD89FB60-A183-4AC0-E040-BB89AD4312AF","latestVersionIndicator":"Yes","beginDate":"2011-09-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-3698-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Surgery","valueDescription":"Surgery","ValueMeaning":{"publicId":"2570738","version":"1","preferredName":"Surgery","longName":"2570738","preferredDefinition":"Surgery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E15F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-36A2-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Stem cell transplant","valueDescription":"Stem cell transplant","ValueMeaning":{"publicId":"2563823","version":"1","preferredName":"Stem cell transplant","longName":"2563823","preferredDefinition":"Stem cell transplant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C65C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-23","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-36AC-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"Chemotherapy","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"2570169","version":"1","preferredName":"Chemotherapy","longName":"2570169","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DF26-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B92BDDE2-36B6-C61C-E040-BB89AD4317D7","beginDate":"2012-02-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","deletedIndicator":"No"},{"value":"External Beam Radiation Therapy","valueDescription":"External Beam Radiation Therapy","ValueMeaning":{"publicId":"2577705","version":"1","preferredName":"External Beam Radiation Therapy","longName":"2577705","preferredDefinition":"(ray-dee-AY-shun) Radiation therapy that uses a machine to aim high-energy rays at the cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"External Beam Radiation Therapy","conceptCode":"C15751","definition":"Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC96-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-16","modifiedBy":"ONEDATA","dateModified":"2006-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB1AC9E0-1E0A-0011-E040-BB89AD43531E","beginDate":"2014-06-05","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-05","modifiedBy":"ONEDATA","dateModified":"2014-06-05","deletedIndicator":"No"},{"value":"MIBG therapy","valueDescription":"MIBG therapy","ValueMeaning":{"publicId":"4352437","version":"1","preferredName":"MIBG therapy","longName":"4352437","preferredDefinition":"MIBG therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB1AC9E0-1E14-0011-E040-BB89AD43531E","latestVersionIndicator":"Yes","beginDate":"2014-06-05","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB1AC9E0-1E2D-0011-E040-BB89AD43531E","beginDate":"2014-06-05","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-05","modifiedBy":"ONEDATA","dateModified":"2014-06-05","deletedIndicator":"No"},{"value":"Additional Brentuximab","valueDescription":"Additional Brentuximab","ValueMeaning":{"publicId":"4642818","version":"1","preferredName":"Additional Brentuximab","longName":"4642818","preferredDefinition":"Additional Brentuximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A9BFDBE-30CD-0F94-E050-BB89AD432F1C","latestVersionIndicator":"Yes","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A9BFDBE-30E6-0F94-E050-BB89AD432F1C","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"ONEDATA","dateModified":"2014-12-19","deletedIndicator":"No"},{"value":"Allogeneic stem cell transplant","valueDescription":"Allogeneic stem cell transplant","ValueMeaning":{"publicId":"4740551","version":"1","preferredName":"Allogeneic stem cell transplant","longName":"4740551","preferredDefinition":"Allogeneic stem cell transplant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A69A3C-773E-54AE-E050-BB89AD4304CB","latestVersionIndicator":"Yes","beginDate":"2015-03-06","endDate":null,"createdBy":"TSANE","dateCreated":"2015-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A69A3C-7757-54AE-E050-BB89AD4304CB","beginDate":"2015-03-06","endDate":null,"createdBy":"TSANE","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Autologous stem cell transplant","valueDescription":"Autologous stem cell transplant","ValueMeaning":{"publicId":"4740552","version":"1","preferredName":"Autologous stem cell transplant","longName":"4740552","preferredDefinition":"Autologous stem cell transplant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A69A3C-7761-54AE-E050-BB89AD4304CB","latestVersionIndicator":"Yes","beginDate":"2015-03-06","endDate":null,"createdBy":"TSANE","dateCreated":"2015-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A69A3C-777A-54AE-E050-BB89AD4304CB","beginDate":"2015-03-06","endDate":null,"createdBy":"TSANE","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"34B70FE3-9A20-D37B-E050-BB89AD433F4F","beginDate":"2016-06-07","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-06-07","modifiedBy":"ONEDATA","dateModified":"2016-06-07","deletedIndicator":"No"},{"value":"Vaccine therapy","valueDescription":"Vaccine Therapy","ValueMeaning":{"publicId":"2568332","version":"1","preferredName":"Vaccine Therapy","longName":"2568332","preferredDefinition":"Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaccine Therapy","conceptCode":"C15347","definition":"Immunotherapy using a preparation that usually contains a complex mixture of disease-related antigens, immunopotentiating agents, and immunomodulators, which stimulate the immune system to destroy pathogenic microorganisms or tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7F9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-02","modifiedBy":"REEVESD","dateModified":"2009-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"34B70FE3-9A34-D37B-E050-BB89AD433F4F","beginDate":"2016-06-07","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-06-07","modifiedBy":"ONEDATA","dateModified":"2016-06-07","deletedIndicator":"No"},{"value":"Investigational agents","valueDescription":"Investigational agents","ValueMeaning":{"publicId":"5288272","version":"1","preferredName":"Investigational agents","longName":"5288272","preferredDefinition":"Investigational agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"34B70FE3-9A3E-D37B-E050-BB89AD433F4F","latestVersionIndicator":"Yes","beginDate":"2016-06-07","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"34B70FE3-9A57-D37B-E050-BB89AD433F4F","beginDate":"2016-06-07","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-06-07","modifiedBy":"ONEDATA","dateModified":"2016-06-07","deletedIndicator":"No"},{"value":"13-cis retinoic acid","valueDescription":"13-cis Retinoic Acid","ValueMeaning":{"publicId":"2578199","version":"1","preferredName":"13-cis Retinoic Acid","longName":"2578199","preferredDefinition":"A topical dermatologic agent that is used in the treatment of acne vulgaris and several other skin diseases. The drug has teratogenic and other adverse effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE84-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"34B70FE3-9A6B-D37B-E050-BB89AD433F4F","beginDate":"2016-06-07","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-06-07","modifiedBy":"ONEDATA","dateModified":"2016-06-07","deletedIndicator":"No"},{"value":"Chemotherapy, Radiation, and Pazopanib","valueDescription":"Chemotherapy, Radiation, and Pazopanib","ValueMeaning":{"publicId":"5487976","version":"1","preferredName":"Chemotherapy, Radiation, and Pazopanib","longName":"5487976","preferredDefinition":"Chemotherapy, Radiation, and Pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D98BF0C-375F-100E-E053-F662850A6FED","latestVersionIndicator":"Yes","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D98BF0C-3778-100E-E053-F662850A6FED","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Chemotherapy and Radiation","valueDescription":"Chemotherapy and Radiation","ValueMeaning":{"publicId":"5487977","version":"1","preferredName":"Chemotherapy and Radiation","longName":"5487977","preferredDefinition":"Chemotherapy and Radiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D98BF0C-3782-100E-E053-F662850A6FED","latestVersionIndicator":"Yes","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D98BF0C-379B-100E-E053-F662850A6FED","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Radiation and Pazopanib","valueDescription":"Radiation and Pazopanib","ValueMeaning":{"publicId":"5487978","version":"1","preferredName":"Radiation and Pazopanib","longName":"5487978","preferredDefinition":"Radiation and Pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D98BF0C-37A5-100E-E053-F662850A6FED","latestVersionIndicator":"Yes","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D98BF0C-37BE-100E-E053-F662850A6FED","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Chemotherapy and Pazopanib","valueDescription":"Chemotherapy and Pazopanib","ValueMeaning":{"publicId":"5487979","version":"1","preferredName":"Chemotherapy and Pazopanib","longName":"5487979","preferredDefinition":"Chemotherapy and Pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D98BF0C-37C8-100E-E053-F662850A6FED","latestVersionIndicator":"Yes","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D98BF0C-37E1-100E-E053-F662850A6FED","beginDate":"2016-09-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-28","modifiedBy":"ONEDATA","dateModified":"2016-09-28","deletedIndicator":"No"},{"value":"Pazopanib","valueDescription":"Pazopanib","ValueMeaning":{"publicId":"3107591","version":"1","preferredName":"Pazopanib","longName":"3107591v1.00","preferredDefinition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pazopanib","conceptCode":"C74547","definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8873406C-1138-C1CB-E040-BB89AD434472","latestVersionIndicator":"Yes","beginDate":"2010-06-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-06-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3CE2E360-731E-237F-E053-F662850A0CAB","beginDate":"2016-09-19","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-19","modifiedBy":"ONEDATA","dateModified":"2016-09-19","deletedIndicator":"No"},{"value":"Immunotherapy","valueDescription":"Immunotherapy","ValueMeaning":{"publicId":"2558928","version":"1","preferredName":"Immunotherapy","longName":"2558928","preferredDefinition":"(IM-yoo-no-THER-a-pee) Treatment to stimulate or restore the ability of the immune system to fight infections and other diseases. Also used to lessen side effects that may be caused by some cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B33D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2009-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415C7E3F-461C-0C32-E053-F662850A7C77","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"Radiation therapy involving liver","valueDescription":"Radiation therapy involving liver","ValueMeaning":{"publicId":"5589119","version":"1","preferredName":"Radiation therapy involving liver","longName":"5589119","preferredDefinition":"Radiation therapy involving liver","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B53099-7B0F-042D-E053-F662850AC8BA","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42B53099-7B28-042D-E053-F662850AC8BA","beginDate":"2016-12-02","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-02","modifiedBy":"ONEDATA","dateModified":"2016-12-02","deletedIndicator":"No"},{"value":"Other immunotherapy (including blinatumomab)","valueDescription":"Other immunotherapy (including blinatumomab)","ValueMeaning":{"publicId":"5589120","version":"1","preferredName":"Other immunotherapy (including blinatumomab)","longName":"5589120","preferredDefinition":"Other immunotherapy (including blinatumomab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B53099-7B32-042D-E053-F662850AC8BA","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42B53099-7B4B-042D-E053-F662850AC8BA","beginDate":"2016-12-02","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-02","modifiedBy":"ONEDATA","dateModified":"2016-12-02","deletedIndicator":"No"},{"value":"HSCT","valueDescription":"HSCT","ValueMeaning":{"publicId":"5589121","version":"1","preferredName":"HSCT","longName":"5589121","preferredDefinition":"HSCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B53099-7B55-042D-E053-F662850AC8BA","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42B53099-7B6E-042D-E053-F662850AC8BA","beginDate":"2016-12-02","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-02","modifiedBy":"ONEDATA","dateModified":"2016-12-02","deletedIndicator":"No"},{"value":"Chimeric antigen receptor T cells","valueDescription":"Chimeric antigen receptor T cells","ValueMeaning":{"publicId":"5589283","version":"1","preferredName":"Chimeric antigen receptor T cells","longName":"5589283","preferredDefinition":"Chimeric antigen receptor T cells","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42EE4D63-F25E-54BA-E053-F662850A74AA","latestVersionIndicator":"Yes","beginDate":"2016-12-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42EE4D63-F277-54BA-E053-F662850A74AA","beginDate":"2016-12-05","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-12-05","modifiedBy":"ONEDATA","dateModified":"2016-12-05","deletedIndicator":"No"},{"value":"Biological Therapy","valueDescription":"Biological Therapy","ValueMeaning":{"publicId":"3198847","version":"1","preferredName":"Biological Therapy","longName":"3198847","preferredDefinition":"Biological therapy is a form of treatment that implies the administration of substances which produce a biological reaction in the organism enhancing or restoring the host immune response, modifying the behavior of cancer cells, blocking the pathways of cell neoplastic transformation and tumor ability to metastasize, or facilitating the repairment of cells damaged by aggressive forms of cancer treatment.  It includes the use of sera, antitoxins, vaccines, genes, cells, tissues, and organs","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biological Therapy","conceptCode":"C15187","definition":"A type of treatment that uses substances derived from or made by living organisms to treat disease; this includes both naturally occurring and synthetic products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D999C94-A599-E80A-E040-BB89AD4330DB","latestVersionIndicator":"Yes","beginDate":"2011-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"719DA265-FBC2-5668-E053-F662850A93BF","beginDate":"2018-07-22","endDate":null,"createdBy":"TANGL","dateCreated":"2018-07-22","modifiedBy":"ONEDATA","dateModified":"2018-07-22","deletedIndicator":"No"},{"value":"Cellular therapy","valueDescription":"Cellular Therapy","ValueMeaning":{"publicId":"4666954","version":"1","preferredName":"Cellular Therapy","longName":"4666954","preferredDefinition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CA258B6-2CAE-90DB-E050-BB89AD4330D1","latestVersionIndicator":"Yes","beginDate":"2015-01-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F889649-E258-1965-E053-F662850A346B","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"},{"value":"ALK inhibitor (crizotinib, lorlatinib, etc)","valueDescription":"Crizotinib Lorlatinib ALK Inhibitor","ValueMeaning":{"publicId":"6614558","version":"1","preferredName":"Crizotinib Lorlatinib ALK Inhibitor","longName":"6614558","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.: An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.: Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lorlatinib","conceptCode":"C113655","definition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"ALK Inhibitor","conceptCode":"C141136","definition":"Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F889649-E28E-1965-E053-F662850A346B","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F889649-E2A7-1965-E053-F662850A346B","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"},{"value":"Investigational or targeted agents (e.g., sorafenib, pazopanib)","valueDescription":"Targeted Molecular Therapy Sorafenib Pazopanib Investigational New Drug","ValueMeaning":{"publicId":"6614557","version":"1","preferredName":"Targeted Molecular Therapy Sorafenib Pazopanib Investigational New Drug","longName":"6614557","preferredDefinition":"Cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread.: A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.: A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.: A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Targeted Molecular Therapy","conceptCode":"C76243","definition":"Cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pazopanib","conceptCode":"C74547","definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Investigational New Drug","conceptCode":"C49135","definition":"A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F889649-E267-1965-E053-F662850A346B","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F889649-E280-1965-E053-F662850A346B","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"},{"value":"Car T-cell therapy","valueDescription":"Car T-cell therapy","ValueMeaning":{"publicId":"6810499","version":"1","preferredName":"Car T-cell therapy","longName":"6810499","preferredDefinition":"A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CA3AC88-AA6F-6BB8-E053-F662850AE5C0","latestVersionIndicator":"Yes","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CA3AC88-AA88-6BB8-E053-F662850AE5C0","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","deletedIndicator":"No"},{"value":"Other cellular immunotherapy","valueDescription":"Other cellular immunotherapy","ValueMeaning":{"publicId":"6810500","version":"1","preferredName":"Other cellular immunotherapy","longName":"6810500","preferredDefinition":"A treatment other than what has been previously specified to stimulate or restore the ability of the immune system to fight infections and other diseases. Also used to lessen side effects that may be caused by some cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CA3AC88-AA92-6BB8-E053-F662850AE5C0","latestVersionIndicator":"Yes","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CA3AC88-AAAB-6BB8-E053-F662850AE5C0","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","deletedIndicator":"No"},{"value":"Immunotherapy (non-cellular)","valueDescription":"Immunotherapy (non-cellular)","ValueMeaning":{"publicId":"6810501","version":"1","preferredName":"Immunotherapy (non-cellular)","longName":"6810501","preferredDefinition":"A treatment to stimulate or restore the ability of the immune system to fight infections and other diseases by no cellular means. Also used to lessen side effects that may be caused by some cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CA3AC88-AAB5-6BB8-E053-F662850AE5C0","latestVersionIndicator":"Yes","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-07","changeDescription":null,"administrativeNotes":"2023.9.7 Alt VM added per ticket request CADSR0002816. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CA3AC88-AACE-6BB8-E053-F662850AE5C0","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","deletedIndicator":"No"},{"value":"Combination Chemoimmunotherapy as per ANBL1221 or similar regimen","valueDescription":"Chemoimmunotherapy","ValueMeaning":{"publicId":"6834270","version":"1","preferredName":"Chemoimmunotherapy","longName":"6834270","preferredDefinition":"Chemotherapy combined with immunotherapy. Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemoimmunotherapy","conceptCode":"C94251","definition":"Chemotherapy combined with immunotherapy. Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9D9613-0AF7-0170-E053-F662850ADBE1","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-26","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9D9613-0B10-0170-E053-F662850ADBE1","beginDate":"2019-07-26","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Tandem stem cell transplant","valueDescription":"Tandem Hematopoietic Stem Cell Transplantation","ValueMeaning":{"publicId":"6834272","version":"1","preferredName":"Tandem Hematopoietic Stem Cell Transplantation","longName":"6834272","preferredDefinition":"A type of autologous stem cell transplant, during which the patient receives two sequential courses of high-dose chemotherapy with stem cell transplant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tandem Hematopoietic Stem Cell Transplantation","conceptCode":"C116469","definition":"A type of autologous stem cell transplant, during which the patient receives two sequential courses of high-dose chemotherapy with stem cell transplant.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9D9613-0B1D-0170-E053-F662850ADBE1","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E9D9613-0B36-0170-E053-F662850ADBE1","beginDate":"2019-07-26","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"Single stem cell transplant","valueDescription":"Single stem cell transplant","ValueMeaning":{"publicId":"6835254","version":"1","preferredName":"Single stem cell transplant","longName":"6835254","preferredDefinition":"single stem cell transplant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED4826A-6C5F-785A-E053-F662850A1A1D","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED4826A-6C78-785A-E053-F662850A1A1D","beginDate":"2019-07-29","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"XRT","valueDescription":"XRT","ValueMeaning":{"publicId":"7044946","version":"1","preferredName":"XRT","longName":"7044946","preferredDefinition":"Radiation therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96C72D34-B49F-16D2-E053-F662850A3042","latestVersionIndicator":"Yes","beginDate":"2019-11-07","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-11-07","modifiedBy":"ONEDATA","dateModified":"2019-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"96C72D34-B4B8-16D2-E053-F662850A3042","beginDate":"2019-11-07","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-11-07","modifiedBy":"ONEDATA","dateModified":"2019-11-07","deletedIndicator":"No"},{"value":"Chemotherapy/Immunotherapy","valueDescription":"Chemotherapy/Immunotherapy","ValueMeaning":{"publicId":"4922115","version":"1","preferredName":"Chemotherapy/Immunotherapy","longName":"4922115","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.: Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1BDFC67B-E901-E2F5-E050-BB89AD4313C0","latestVersionIndicator":"Yes","beginDate":"2015-07-27","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0F19AB5-283C-37EE-E053-4EBD850A6E60","beginDate":"2020-10-05","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-05","modifiedBy":"ONEDATA","dateModified":"2020-10-05","deletedIndicator":"No"},{"value":"External Beam Radiotherapy","valueDescription":"Radiation Therapy External Beam","ValueMeaning":{"publicId":"7425362","version":"1","preferredName":"Radiation Therapy External Beam","longName":"7425362","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: Happening or arising or located outside or beyond some limits, or especially, some surface.: A group of nearly parallel rays of electromagnetic radiation or a stream of particles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"External","conceptCode":"C44280","definition":"Happening or arising or located outside or beyond some limits, or especially, some surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Beam","conceptCode":"C70569","definition":"A group of nearly parallel rays of electromagnetic radiation or a stream of particles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF76281F-D474-5F98-E053-4EBD850AF417","latestVersionIndicator":"Yes","beginDate":"2020-09-16","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF76281F-D48D-5F98-E053-4EBD850AF417","beginDate":"2020-09-16","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-16","modifiedBy":"ONEDATA","dateModified":"2020-09-16","deletedIndicator":"No"},{"value":"Isotretinoin","valueDescription":"Isotretinoin","ValueMeaning":{"publicId":"3379087","version":"1","preferredName":"Isotretinoin","longName":"3379087","preferredDefinition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5638-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF76281F-D497-5F98-E053-4EBD850AF417","beginDate":"2020-09-16","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-16","modifiedBy":"ONEDATA","dateModified":"2020-09-16","deletedIndicator":"No"},{"value":"Chimeric antigen receptor T cell therapy","valueDescription":"Chimeric antigen receptor T cell therapy","ValueMeaning":{"publicId":"6829535","version":"1","preferredName":"Chimeric antigen receptor T cell therapy","longName":"6829535","preferredDefinition":"Chimeric antigen receptor T cell therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6D62-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A7F96C-5097-0B07-E053-4EBD850ACC50","beginDate":"2021-04-23","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"DFMO","valueDescription":"Eflornithine","ValueMeaning":{"publicId":"7743034","version":"1","preferredName":"Eflornithine","longName":"7743034","preferredDefinition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eflornithine","conceptCode":"C226","definition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7820140-954D-6978-E053-4EBD850A0D47","latestVersionIndicator":"Yes","beginDate":"2021-07-19","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7820140-9566-6978-E053-4EBD850A0D47","beginDate":"2021-07-19","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA31C11C-26C3-0324-E053-4EBD850A4A81","beginDate":"2022-03-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-14","modifiedBy":"ONEDATA","dateModified":"2022-03-14","deletedIndicator":"No"},{"value":"Donor Lymphocyte Infusion","valueDescription":"Donor Leukocyte Infusion","ValueMeaning":{"publicId":"2866902","version":"1","preferredName":"Donor Leukocyte Infusion","longName":"2866902","preferredDefinition":"A type of therapy in which lymphocytes from the blood of a donor are given to a patient who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Donor lymphocyte infusion is used to treat chronic myelogenous leukemia (CML) that has come back and myeloma. It is being studied in the treatment of other types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donor Lymphocyte Infusion","conceptCode":"C16145","definition":"The infusion of donor lymphocytes following hematopoietic stem cell transplantation for the purpose of augmenting the host immune response or preventing the rejection of the graft.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68DF7602-9A6D-3F9A-E040-BB89AD43599F","latestVersionIndicator":"Yes","beginDate":"2009-05-01","endDate":null,"createdBy":"CZECHS","dateCreated":"2009-05-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA31C11C-26D7-0324-E053-4EBD850A4A81","beginDate":"2022-03-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-14","modifiedBy":"ONEDATA","dateModified":"2022-03-14","deletedIndicator":"No"},{"value":"Cellular Therapy","valueDescription":"Cellular Therapy","ValueMeaning":{"publicId":"4666954","version":"1","preferredName":"Cellular Therapy","longName":"4666954","preferredDefinition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CA258B6-2CAE-90DB-E050-BB89AD4330D1","latestVersionIndicator":"Yes","beginDate":"2015-01-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA31C11C-26E1-0324-E053-4EBD850A4A81","beginDate":"2022-03-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-14","modifiedBy":"ONEDATA","dateModified":"2022-03-14","deletedIndicator":"No"},{"value":"Antibody Therapy","valueDescription":"Antibody Therapy","ValueMeaning":{"publicId":"6620407","version":"1","preferredName":"Antibody Therapy","longName":"6620407","preferredDefinition":"Treatment with injections of antibodies made in another animal or in the laboratory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibody Therapy","conceptCode":"C15542","definition":"Treatment with injections of antibodies to directly destroy specific, usually cancerous, cells or to stimulate the immune system to destroy those cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80A284BD-65FC-7509-E053-F662850A5839","latestVersionIndicator":"Yes","beginDate":"2019-01-29","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-29","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA31C11C-26F5-0324-E053-4EBD850A4A81","beginDate":"2022-03-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-14","modifiedBy":"ONEDATA","dateModified":"2022-03-14","deletedIndicator":"No"},{"value":"Epigenetic agent such as azacitidine and decitabine","valueDescription":null,"ValueMeaning":{"publicId":"10927747","version":"1","preferredName":"Epigenetic agent such as azacitidine and decitabine","longName":"10927747v1.00","preferredDefinition":"Epigenetic agent such as azacitidine and decitabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E555F6D7-A6AF-5CCA-E053-731AD00A5181","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E555F6D7-A6B1-5CCA-E053-731AD00A5181","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Epigenetic modifier (e.g. azacitidine, decitabine)","valueDescription":null,"ValueMeaning":{"publicId":"10927748","version":"1","preferredName":"Epigenetic modifier (e.g. azacitidine, decitabine)","longName":"10927748v1.00","preferredDefinition":"Epigenetic modifier (e.g. azacitidine, decitabine)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E555F6D7-A6B0-5CCA-E053-731AD00A5181","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E555F6D7-A6B2-5CCA-E053-731AD00A5181","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Intrathecal chemotherapy","valueDescription":null,"ValueMeaning":{"publicId":"5143296","version":"1","preferredName":"Intrathecal Chemotherapy","longName":"5143296","preferredDefinition":"Treatment in which anticancer drugs are injected into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Chemotherapy","conceptCode":"C15750","definition":"Chemotherapy delivered via the spinal canal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CB1C481-C5A4-1475-E050-BB89AD433B19","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E55610D5-4AF0-600C-E053-731AD00ABF11","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Cranial radiation","valueDescription":null,"ValueMeaning":{"publicId":"10927749","version":"1","preferredName":"Cranial Radiation Therapy","longName":"10927749v1.00","preferredDefinition":"Of or relating to the cranium._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cranial","conceptCode":"C37936","definition":"Of or relating to the cranium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E55610D5-4AEE-600C-E053-731AD00ABF11","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":null,"administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E55610D5-4AF1-600C-E053-731AD00ABF11","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Craniospinal radiation","valueDescription":null,"ValueMeaning":{"publicId":"5028294","version":"1","preferredName":"Craniospinal Irradiation","longName":"5028294","preferredDefinition":"The use of radiation therapy directed at the brain and spinal cord to kill cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniospinal Irradiation","conceptCode":"C116437","definition":"The use of radiation therapy directed at the brain and spinal cord to kill cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2189EF50-FFA7-CB37-E050-BB89AD437EA1","latestVersionIndicator":"Yes","beginDate":"2015-10-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E55610D5-4AF2-600C-E053-731AD00ABF11","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Testicular radiation","valueDescription":null,"ValueMeaning":{"publicId":"10927750","version":"1","preferredName":"Testis Radiation Therapy","longName":"10927750v1.00","preferredDefinition":"Either of the paired male reproductive glands that produce the male germ cells and the male hormones._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testis","conceptCode":"C12412","definition":"Either of the paired male reproductive glands that produce the male germ cells and the male hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E55610D5-4AEF-600C-E053-731AD00ABF11","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E55610D5-4AF3-600C-E053-731AD00ABF11","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"FLT-3 inhibitor","valueDescription":null,"ValueMeaning":{"publicId":"10927751","version":"1","preferredName":"FLT3 Inhibitor","longName":"10927751v1.00","preferredDefinition":"Any drug or substance that inhibits the activity of receptor-type tyrosine-protein kinase FLT3 protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FLT3 Inhibitor","conceptCode":"C124800","definition":"Any drug or substance that inhibits the activity of receptor-type tyrosine-protein kinase FLT3 protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5562126-84E5-61A7-E053-731AD00A0A7D","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5562126-84E7-61A7-E053-731AD00A0A7D","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Tyrosine kinase inhibitor","valueDescription":null,"ValueMeaning":{"publicId":"5127433","version":"1","preferredName":"Tyrosine Kinase Inhibitor","longName":"5127433","preferredDefinition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB7E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5562126-84E8-61A7-E053-731AD00A0A7D","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Venetoclax","valueDescription":null,"ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5562126-84E9-61A7-E053-731AD00A0A7D","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Bcl-2 inhibitor","valueDescription":null,"ValueMeaning":{"publicId":"10927752","version":"1","preferredName":"BCL-2 Inhibitor","longName":"10927752v1.00","preferredDefinition":"Any agent that inhibits the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2; Bcl2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCL-2 Inhibitor","conceptCode":"C159200","definition":"Any agent that inhibits the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2; Bcl2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5562126-84E6-61A7-E053-731AD00A0A7D","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5562126-84EA-61A7-E053-731AD00A0A7D","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"FLT-3 inhibitor (e.g. sorafenib, gilteritinib)","valueDescription":null,"ValueMeaning":{"publicId":"10927753","version":"1","preferredName":"FLT-3 inhibitor (e.g. sorafenib, gilteritinib)","longName":"10927753v1.00","preferredDefinition":"FLT-3 inhibitor (e.g. sorafenib, gilteritinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5562CD5-FD80-62CF-E053-731AD00A4E69","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5562CD5-FD82-62CF-E053-731AD00A4E69","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Tyrosine kinase inhibitor (e.g. dasatinib, imatinib)","valueDescription":null,"ValueMeaning":{"publicId":"10927754","version":"1","preferredName":"Tyrosine kinase inhibitor (e.g. dasatinib, imatinib)","longName":"10927754v1.00","preferredDefinition":"Tyrosine kinase inhibitor (e.g. dasatinib, imatinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5562CD5-FD81-62CF-E053-731AD00A4E69","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5562CD5-FD83-62CF-E053-731AD00A4E69","beginDate":"2022-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Intra-arterial therapy","valueDescription":null,"ValueMeaning":{"publicId":"11235028","version":"1","preferredName":"Intra-arterial Therapeutic Procedure","longName":"11235028v1.00","preferredDefinition":"Within an artery (blood vessel that carries blood from the heart to tissues and organs in the body)._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intra-arterial","conceptCode":"C94248","definition":"Within an artery (blood vessel that carries blood from the heart to tissues and organs in the body).","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8942BB5-9C9A-4CCC-E053-731AD00AA460","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8942BB5-9C9C-4CCC-E053-731AD00AA460","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Other non-protocol chemotherapy","valueDescription":null,"ValueMeaning":{"publicId":"11235029","version":"1","preferredName":"Other Negation Protocol Chemotherapy","longName":"11235029v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned._An operation in which a term denies or inverts the meaning of another term or construction._A rule which guides how an activity should be performed._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8942BB5-9C9B-4CCC-E053-731AD00AA460","latestVersionIndicator":"Yes","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8942BB5-9C9D-4CCC-E053-731AD00AA460","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Enucleation","valueDescription":null,"ValueMeaning":{"publicId":"2577243","version":"1","preferredName":"Enucleation","longName":"2577243","preferredDefinition":"A surgical procedure by which tissue or an organ (usually containing a tumor) is removed without rupture from a specific anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enucleation","conceptCode":"C48601","definition":"A surgical procedure by which tissue or an organ (usually containing a tumor) is removed without rupture from a specific anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FAC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8942BB5-9C9E-4CCC-E053-731AD00AA460","beginDate":"2022-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","deletedIndicator":"No"},{"value":"Cryoablation","valueDescription":null,"ValueMeaning":{"publicId":"3648722","version":"1","preferredName":"Cryosurgery","longName":"3648722","preferredDefinition":"The removal of a body part, pathway, or function by freezing the desired entity. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cryosurgery","conceptCode":"C15215","definition":"The use of extreme cold to damage or destroy a body part, pathway, or function. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2687837-1EE5-65C4-E040-BB89AD432ADD","latestVersionIndicator":"Yes","beginDate":"2013-01-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CB525B-1688-1714-E053-731AD00AC5D0","beginDate":"2022-09-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","deletedIndicator":"No"},{"value":"Green laser photoablation","valueDescription":null,"ValueMeaning":{"publicId":"11253494","version":"1","preferredName":"Green laser photoablation","longName":"11253494v1.00","preferredDefinition":"Green laser photoablation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CB525B-1685-1714-E053-731AD00AC5D0","latestVersionIndicator":"Yes","beginDate":"2022-09-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CB525B-1689-1714-E053-731AD00AC5D0","beginDate":"2022-09-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","deletedIndicator":"No"},{"value":"Infrared laser photoablation","valueDescription":null,"ValueMeaning":{"publicId":"11253495","version":"1","preferredName":"Infrared laser photoablation","longName":"11253495v1.00","preferredDefinition":"Infrared laser photoablation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CB525B-1686-1714-E053-731AD00AC5D0","latestVersionIndicator":"Yes","beginDate":"2022-09-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CB525B-168A-1714-E053-731AD00AC5D0","beginDate":"2022-09-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","deletedIndicator":"No"},{"value":"Local (focal) Radiation Therapy","valueDescription":null,"ValueMeaning":{"publicId":"11253496","version":"1","preferredName":"Focal Radiation Therapy","longName":"11253496v1.00","preferredDefinition":"Limited to a specific area._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Focal","conceptCode":"C28224","definition":"Limited to a specific area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CB525B-1687-1714-E053-731AD00AC5D0","latestVersionIndicator":"Yes","beginDate":"2022-09-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CB525B-168B-1714-E053-731AD00AC5D0","beginDate":"2022-09-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-16","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","deletedIndicator":"No"},{"value":"Cabozantinib","valueDescription":null,"ValueMeaning":{"publicId":"6824783","version":"1","preferredName":"Cabozantinib","longName":"6824783","preferredDefinition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabozantinib","conceptCode":"C52200","definition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6CBDA5-622A-0BC1-E053-F662850A520D","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDAB757E-06A6-4441-E053-731AD00A6003","beginDate":"2022-11-17","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-11-17","modifiedBy":"CLOHNES","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Chemotherapy and cabozantinib","valueDescription":null,"ValueMeaning":{"publicId":"12077176","version":"1","preferredName":"Chemotherapy And Cabozantinib","longName":"12077176v1.00","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cabozantinib","conceptCode":"C52200","definition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDAB8E51-7D32-46CC-E053-731AD00AD013","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-11-17","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDAB8E51-7D33-46CC-E053-731AD00AD013","beginDate":"2022-11-17","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-11-17","modifiedBy":"CLOHNES","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Additional surgery","valueDescription":null,"ValueMeaning":{"publicId":"12077182","version":"1","preferredName":"Additional Surgery","longName":"12077182v1.00","preferredDefinition":"Added; extra; further._The branch of medical science that treats disease or injury by operative procedures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Surgery","conceptCode":"C17173","definition":"The branch of medical science that treats disease or injury by operative procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDABC216-5B4B-4BF4-E053-731AD00AEFA7","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-11-17","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDABC216-5B4C-4BF4-E053-731AD00AEFA7","beginDate":"2022-11-17","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-11-17","modifiedBy":"CLOHNES","dateModified":"2022-11-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3379559","version":"1","preferredName":"Current Therapy Type","preferredDefinition":"The name of the therapy that is currently being administered.:Something distinguishable as an identifiable class based on common qualities.","longName":"C85582:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current Therapy","conceptCode":"C85582","definition":"The name of the therapy that is currently being administered.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-365F-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-17","modifiedBy":"ONEDATA","dateModified":"2012-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3670-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-17","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":"Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":"2022.9.13 Added PVs for ticket request CADSR0001486. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Which therapy was delayed?","type":"Preferred Question Text","description":"Which therapy was delayed?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3CF589EE-4188-6473-E053-F662850A2829","latestVersionIndicator":"Yes","beginDate":"2016-09-20","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-09-20","modifiedBy":"KUMMEROA","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":"2022.10.13 Retired per Thalia Beeles at COG. ak 2022.11.16 Took out of retirement, reviewed and released due to use on forms. ak","unresolvedIssues":null,"deletedIndicator":"No"}}